Review



15cbs 0243c  (Carna Inc)


Bioz Verified Symbol Carna Inc is a verified supplier
Bioz Manufacturer Symbol Carna Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Carna Inc 15cbs 0243c
    15cbs 0243c, supplied by Carna Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/02-139/DCAMKL1/pm33762936-36-14-15
    Average 94 stars, based on 1 article reviews
    15cbs 0243c - by Bioz Stars, 2026-11
    94/100 stars

    Images

    Related Articles

    In Vitro:

    Article Title: XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression.
    Article Snippet: .. In Vitro Kinase Assa Purified kinase-active DCLK1 0.25 μg (cat. no., 02-139, lot. no., 15CBS-0243C; Carna Biosciences, Inc.) was incubated in kinase buffer (50 mM HEPES, pH 7.5; 0.01% Tween-20; 10 mM MgCl2; 1 mM EGTA) with 2.5 μg ULight-CREBtide peptide (cat. no., TRF0200-D; lot. no., 2427110; PerkinElmer, Inc.), 1 μM ATP (Merck KGaA), and either DMSO or XMD17-51 (the compounds were tested from 10 μM, 3-fold dilution, 10 concentration points) for 1 h at 30°C. ..

    Purification:

    Article Title: XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression.
    Article Snippet: .. In Vitro Kinase Assa Purified kinase-active DCLK1 0.25 μg (cat. no., 02-139, lot. no., 15CBS-0243C; Carna Biosciences, Inc.) was incubated in kinase buffer (50 mM HEPES, pH 7.5; 0.01% Tween-20; 10 mM MgCl2; 1 mM EGTA) with 2.5 μg ULight-CREBtide peptide (cat. no., TRF0200-D; lot. no., 2427110; PerkinElmer, Inc.), 1 μM ATP (Merck KGaA), and either DMSO or XMD17-51 (the compounds were tested from 10 μM, 3-fold dilution, 10 concentration points) for 1 h at 30°C. ..

    Article Title: XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression
    Article Snippet: .. Purified kinase-active DCLK1 0.25 μg (cat. no., 02-139, lot. no., 15CBS-0243C; Carna Biosciences, Inc.) was incubated in kinase buffer (50 mM HEPES, pH 7.5; 0.01% Tween-20; 10 mM MgCl 2 ; 1 mM EGTA) with 2.5 μg ULight-CREBtide peptide (cat. no., TRF0200-D; lot. no., 2427110; PerkinElmer, Inc.), 1 μM ATP (Merck KGaA), and either DMSO or XMD-17-51 (the compounds were tested from 10 μM, 3-fold dilution, 10 concentration points) for 1 h at 30°C. ..

    Incubation:

    Article Title: XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression.
    Article Snippet: .. In Vitro Kinase Assa Purified kinase-active DCLK1 0.25 μg (cat. no., 02-139, lot. no., 15CBS-0243C; Carna Biosciences, Inc.) was incubated in kinase buffer (50 mM HEPES, pH 7.5; 0.01% Tween-20; 10 mM MgCl2; 1 mM EGTA) with 2.5 μg ULight-CREBtide peptide (cat. no., TRF0200-D; lot. no., 2427110; PerkinElmer, Inc.), 1 μM ATP (Merck KGaA), and either DMSO or XMD17-51 (the compounds were tested from 10 μM, 3-fold dilution, 10 concentration points) for 1 h at 30°C. ..

    Article Title: XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression
    Article Snippet: .. Purified kinase-active DCLK1 0.25 μg (cat. no., 02-139, lot. no., 15CBS-0243C; Carna Biosciences, Inc.) was incubated in kinase buffer (50 mM HEPES, pH 7.5; 0.01% Tween-20; 10 mM MgCl 2 ; 1 mM EGTA) with 2.5 μg ULight-CREBtide peptide (cat. no., TRF0200-D; lot. no., 2427110; PerkinElmer, Inc.), 1 μM ATP (Merck KGaA), and either DMSO or XMD-17-51 (the compounds were tested from 10 μM, 3-fold dilution, 10 concentration points) for 1 h at 30°C. ..

    Concentration Assay:

    Article Title: XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression.
    Article Snippet: .. In Vitro Kinase Assa Purified kinase-active DCLK1 0.25 μg (cat. no., 02-139, lot. no., 15CBS-0243C; Carna Biosciences, Inc.) was incubated in kinase buffer (50 mM HEPES, pH 7.5; 0.01% Tween-20; 10 mM MgCl2; 1 mM EGTA) with 2.5 μg ULight-CREBtide peptide (cat. no., TRF0200-D; lot. no., 2427110; PerkinElmer, Inc.), 1 μM ATP (Merck KGaA), and either DMSO or XMD17-51 (the compounds were tested from 10 μM, 3-fold dilution, 10 concentration points) for 1 h at 30°C. ..

    Article Title: XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression
    Article Snippet: .. Purified kinase-active DCLK1 0.25 μg (cat. no., 02-139, lot. no., 15CBS-0243C; Carna Biosciences, Inc.) was incubated in kinase buffer (50 mM HEPES, pH 7.5; 0.01% Tween-20; 10 mM MgCl 2 ; 1 mM EGTA) with 2.5 μg ULight-CREBtide peptide (cat. no., TRF0200-D; lot. no., 2427110; PerkinElmer, Inc.), 1 μM ATP (Merck KGaA), and either DMSO or XMD-17-51 (the compounds were tested from 10 μM, 3-fold dilution, 10 concentration points) for 1 h at 30°C. ..



    Similar Products

    94
    Carna Inc 15cbs 0243c
    15cbs 0243c, supplied by Carna Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/02-139/DCAMKL1/pm33762936-36-14-15
    Average 94 stars, based on 1 article reviews
    15cbs 0243c - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    99
    Vazyme Biotech Co 139 chamq sybr qpcr master mix
    139 Chamq Sybr Qpcr Master Mix, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/02-139/ChamQ+SYBR+qPCR+Master+Mix/pm42822740-73-18-24
    Average 99 stars, based on 1 article reviews
    139 chamq sybr qpcr master mix - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    Vazyme Biotech Co chamq universal 139 sybr qpcr master mix kit
    Chamq Universal 139 Sybr Qpcr Master Mix Kit, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/02-139/ChamQ+Universal+SYBR+qPCR+Master+Mix/pm41331798-65-5-14
    Average 99 stars, based on 1 article reviews
    chamq universal 139 sybr qpcr master mix kit - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    96
    Vazyme Biotech Co aceq qpcr probe 139 master mix
    Aceq Qpcr Probe 139 Master Mix, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/02-139/AceQ+Universal+U%2B+Probe+Master+Mix+V2/pm40819779-76-9-16
    Average 96 stars, based on 1 article reviews
    aceq qpcr probe 139 master mix - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    99
    Vazyme Biotech Co hiscript iii 1st strand cdna synthesis 139 kit
    Hiscript Iii 1st Strand Cdna Synthesis 139 Kit, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/02-139/HiScript+III+1st+Strand+cDNA+Synthesis+Kit+%2BgDNA+wiper/pm40753760-60-13-23
    Average 99 stars, based on 1 article reviews
    hiscript iii 1st strand cdna synthesis 139 kit - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    94
    Tecan Systems 139 hydroflex plate washer
    139 Hydroflex Plate Washer, supplied by Tecan Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/02-139/HydroFlex/10__1128_slash_jcm__02107___20-57-19-18
    Average 94 stars, based on 1 article reviews
    139 hydroflex plate washer - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Carna Inc dclk1
    FIGURE 1 | XMD-17-51 inhibits <t>DCLK1</t> kinase activity. (A) Molecular structure of XMD-17-51. (B) XMD-17-51 inhibited DCLK1 kinase activity in an in vitro kinase assay performed using purified active DCLK1 kinase. (C) XMD-17-51 decreased DCLK1 mRNA expression levels in A549 cells, as shown by RT-qPCR (normalization to GAPDH levels). Data are presented as fold change relative to the DCLK1 levels in vehicle control cells. (D) DCLK1 and its downstream target protein level in A549 cells were decreased significantly following treatment with XMD-17-51, GAPDH was used as a loading control. The data shown are (A,D) representative of or (B,C) are presented as the mean ± SD of at least three independent experiments. DCLK1, doublecortin-like kinase 1.
    Dclk1, supplied by Carna Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/02-139/DCAMKL1/pm33762936-36-6-15
    Average 94 stars, based on 1 article reviews
    dclk1 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    98
    Danaher Inc running buffer hbs ep 10× 139
    FIGURE 1 | XMD-17-51 inhibits <t>DCLK1</t> kinase activity. (A) Molecular structure of XMD-17-51. (B) XMD-17-51 inhibited DCLK1 kinase activity in an in vitro kinase assay performed using purified active DCLK1 kinase. (C) XMD-17-51 decreased DCLK1 mRNA expression levels in A549 cells, as shown by RT-qPCR (normalization to GAPDH levels). Data are presented as fold change relative to the DCLK1 levels in vehicle control cells. (D) DCLK1 and its downstream target protein level in A549 cells were decreased significantly following treatment with XMD-17-51, GAPDH was used as a loading control. The data shown are (A,D) representative of or (B,C) are presented as the mean ± SD of at least three independent experiments. DCLK1, doublecortin-like kinase 1.
    Running Buffer Hbs Ep 10× 139, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/02-139/HEPES/pm30414968-58-12-35
    Average 98 stars, based on 1 article reviews
    running buffer hbs ep 10× 139 - by Bioz Stars, 2026-11
    98/100 stars
      Buy from Supplier

    96
    Omega Bio Tek ezna bacterial dna 139 purification kit
    FIGURE 1 | XMD-17-51 inhibits <t>DCLK1</t> kinase activity. (A) Molecular structure of XMD-17-51. (B) XMD-17-51 inhibited DCLK1 kinase activity in an in vitro kinase assay performed using purified active DCLK1 kinase. (C) XMD-17-51 decreased DCLK1 mRNA expression levels in A549 cells, as shown by RT-qPCR (normalization to GAPDH levels). Data are presented as fold change relative to the DCLK1 levels in vehicle control cells. (D) DCLK1 and its downstream target protein level in A549 cells were decreased significantly following treatment with XMD-17-51, GAPDH was used as a loading control. The data shown are (A,D) representative of or (B,C) are presented as the mean ± SD of at least three independent experiments. DCLK1, doublecortin-like kinase 1.
    Ezna Bacterial Dna 139 Purification Kit, supplied by Omega Bio Tek, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/02-139/10__1094_slash_pdis___10___16___1481___re-46-9-15
    Average 96 stars, based on 1 article reviews
    ezna bacterial dna 139 purification kit - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    Image Search Results


    FIGURE 1 | XMD-17-51 inhibits DCLK1 kinase activity. (A) Molecular structure of XMD-17-51. (B) XMD-17-51 inhibited DCLK1 kinase activity in an in vitro kinase assay performed using purified active DCLK1 kinase. (C) XMD-17-51 decreased DCLK1 mRNA expression levels in A549 cells, as shown by RT-qPCR (normalization to GAPDH levels). Data are presented as fold change relative to the DCLK1 levels in vehicle control cells. (D) DCLK1 and its downstream target protein level in A549 cells were decreased significantly following treatment with XMD-17-51, GAPDH was used as a loading control. The data shown are (A,D) representative of or (B,C) are presented as the mean ± SD of at least three independent experiments. DCLK1, doublecortin-like kinase 1.

    Journal: Frontiers in pharmacology

    Article Title: XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression.

    doi: 10.3389/fphar.2021.603453

    Figure Lengend Snippet: FIGURE 1 | XMD-17-51 inhibits DCLK1 kinase activity. (A) Molecular structure of XMD-17-51. (B) XMD-17-51 inhibited DCLK1 kinase activity in an in vitro kinase assay performed using purified active DCLK1 kinase. (C) XMD-17-51 decreased DCLK1 mRNA expression levels in A549 cells, as shown by RT-qPCR (normalization to GAPDH levels). Data are presented as fold change relative to the DCLK1 levels in vehicle control cells. (D) DCLK1 and its downstream target protein level in A549 cells were decreased significantly following treatment with XMD-17-51, GAPDH was used as a loading control. The data shown are (A,D) representative of or (B,C) are presented as the mean ± SD of at least three independent experiments. DCLK1, doublecortin-like kinase 1.

    Article Snippet: In Vitro Kinase Assa Purified kinase-active DCLK1 0.25 μg (cat. no., 02-139, lot. no., 15CBS-0243C; Carna Biosciences, Inc.) was incubated in kinase buffer (50 mM HEPES, pH 7.5; 0.01% Tween-20; 10 mM MgCl2; 1 mM EGTA) with 2.5 μg ULight-CREBtide peptide (cat. no., TRF0200-D; lot. no., 2427110; PerkinElmer, Inc.), 1 μM ATP (Merck KGaA), and either DMSO or XMD17-51 (the compounds were tested from 10 μM, 3-fold dilution, 10 concentration points) for 1 h at 30°C.

    Techniques: Activity Assay, In Vitro, Kinase Assay, Expressing, Quantitative RT-PCR, Control

    FIGURE 2 | XMD-17-51 inhibits NSCLC cell proliferation via DCLK1. (A) XMD-17-51 inhibited A549, NCI-H1299 and NCI-H1975 cell proliferation, as detected by MTT proliferation assay. (B) DCLK1 overexpression impaired the anti-proliferative activity of XMD-17-51 in A549 cells. (C) DCLK1-knockdown A549 cells demonstrated a significantly decreased resistance to XMD-17-51. Data shown are representative of (graph) or are presented as the mean ± SD (blot) of at least three independent experiments. NSCLC, non-small cell lung carcinoma; DCLK1, doublecortin-like kinase 1; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide.

    Journal: Frontiers in pharmacology

    Article Title: XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression.

    doi: 10.3389/fphar.2021.603453

    Figure Lengend Snippet: FIGURE 2 | XMD-17-51 inhibits NSCLC cell proliferation via DCLK1. (A) XMD-17-51 inhibited A549, NCI-H1299 and NCI-H1975 cell proliferation, as detected by MTT proliferation assay. (B) DCLK1 overexpression impaired the anti-proliferative activity of XMD-17-51 in A549 cells. (C) DCLK1-knockdown A549 cells demonstrated a significantly decreased resistance to XMD-17-51. Data shown are representative of (graph) or are presented as the mean ± SD (blot) of at least three independent experiments. NSCLC, non-small cell lung carcinoma; DCLK1, doublecortin-like kinase 1; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide.

    Article Snippet: In Vitro Kinase Assa Purified kinase-active DCLK1 0.25 μg (cat. no., 02-139, lot. no., 15CBS-0243C; Carna Biosciences, Inc.) was incubated in kinase buffer (50 mM HEPES, pH 7.5; 0.01% Tween-20; 10 mM MgCl2; 1 mM EGTA) with 2.5 μg ULight-CREBtide peptide (cat. no., TRF0200-D; lot. no., 2427110; PerkinElmer, Inc.), 1 μM ATP (Merck KGaA), and either DMSO or XMD17-51 (the compounds were tested from 10 μM, 3-fold dilution, 10 concentration points) for 1 h at 30°C.

    Techniques: Proliferation Assay, Over Expression, Activity Assay, Knockdown

    FIGURE 4 | XMD-17-51 inhibits cancer cell stemness in A549 cells. (A) DCLK1 overexpression promoted sphere formation from A549 cells. Cells (1,000 cells/well) were suspended in stem cell medium. Spheres were counted 7 days after treatment and sphere formation efficiency is presented as the mean ± SD. (B) XMD-17-51 inhibited sphere formation from A549 cells. A549 cells (1,000 cells/well) were suspended in stem cell medium and treated with XMD-17-51 at different concentrations. Spheres were counted 10 days after treatment. Sphere formation efficiency is presented as the mean ± SD. (C) XMD-17-51 decreased cancer stem cell markers of A549 cells, as shown by RT-qPCR (normalization to GAPDH levels). Data are shown as a fold change relative to the levels in vehicle control cells and are presented as mean ± SD. DCLK1, doublecortin-like kinase 1.

    Journal: Frontiers in pharmacology

    Article Title: XMD-17-51 Inhibits DCLK1 Kinase and Prevents Lung Cancer Progression.

    doi: 10.3389/fphar.2021.603453

    Figure Lengend Snippet: FIGURE 4 | XMD-17-51 inhibits cancer cell stemness in A549 cells. (A) DCLK1 overexpression promoted sphere formation from A549 cells. Cells (1,000 cells/well) were suspended in stem cell medium. Spheres were counted 7 days after treatment and sphere formation efficiency is presented as the mean ± SD. (B) XMD-17-51 inhibited sphere formation from A549 cells. A549 cells (1,000 cells/well) were suspended in stem cell medium and treated with XMD-17-51 at different concentrations. Spheres were counted 10 days after treatment. Sphere formation efficiency is presented as the mean ± SD. (C) XMD-17-51 decreased cancer stem cell markers of A549 cells, as shown by RT-qPCR (normalization to GAPDH levels). Data are shown as a fold change relative to the levels in vehicle control cells and are presented as mean ± SD. DCLK1, doublecortin-like kinase 1.

    Article Snippet: In Vitro Kinase Assa Purified kinase-active DCLK1 0.25 μg (cat. no., 02-139, lot. no., 15CBS-0243C; Carna Biosciences, Inc.) was incubated in kinase buffer (50 mM HEPES, pH 7.5; 0.01% Tween-20; 10 mM MgCl2; 1 mM EGTA) with 2.5 μg ULight-CREBtide peptide (cat. no., TRF0200-D; lot. no., 2427110; PerkinElmer, Inc.), 1 μM ATP (Merck KGaA), and either DMSO or XMD17-51 (the compounds were tested from 10 μM, 3-fold dilution, 10 concentration points) for 1 h at 30°C.

    Techniques: Over Expression, Quantitative RT-PCR, Control